Fluvoxamine in the treatment of obsessive-compulsive disorder and related conditions

Journal of Clinical Psychiatry

Volumn 58, Issue SUPPL. 5, 1997, Pages 32-49

  Goodman, Wayne K ^a   Ward, Herbert ^a   Kablinger, Anita ^a   Murphy, Tanya ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; ASTEMIZOLE; CARBAMAZEPINE; CLOMIPRAMINE; CLOZAPINE; CYPROHEPTADINE; DEXFENFLURAMINE; FEXOFENADINE; FLUOXETINE; FLUVOXAMINE; LITHIUM; LORATADINE; LORAZEPAM; METHADONE; NEFAZODONE; OXAZEPAM; PAROXETINE; PHENYTOIN; PROPRANOLOL; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TEMAZEPAM; TERFENADINE; THEOPHYLLINE DERIVATIVE; TRAZODONE; UNINDEXED DRUG; WARFARIN; YOHIMBINE;

ASTHENIA; CLINICAL PROTOCOL; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; HEART VENTRICLE ARRHYTHMIA; HUMAN; NAUSEA; OBSESSION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TERATOGENESIS; TREATMENT INDICATION; XEROSTOMIA;

ADOLESCENT; CHILD; CLINICAL TRIALS; CLOMIPRAMINE; COMPULSIVE BEHAVIOR; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FLUVOXAMINE; HUMANS; IMPULSE CONTROL DISORDERS; OBSESSIVE BEHAVIOR; OBSESSIVE-COMPULSIVE DISORDER; RECURRENCE; SEROTONIN UPTAKE INHIBITORS; SOMATOFORM DISORDERS; TOURETTE SYNDROME;

EID: 0030957724     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (200)

1. Renynghe de Voxrie GV. Anafranil (G 34586) in obsessive neurosis. Acta Neurol Belg 1968;68:787-792
2. Yaryura-Tobias JA, Neziroglu F, Bergman L. Chlorimipramine, for obsession-compulsive neurosis: an organic approach. Current Therapeutic Research 1976;20:541-548
3. The Clomipramine Collaborative Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 1991;48:730-738
4. Zohar J, Insel TR. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment and pathophysiology. Biol Psychiatry 1987;22:667-687
5. Leonard H, Swedo S, Coffey M, et al. Clomipramine vs desipramine in childhood obsessive-compulsive disorder. Psychopharmacol Bull 1988; 24:43-45
6. Rasmussen SA, Goodman WK, Greist JH, et al. Fluvoxamine in the treatment of obsessive-compulsive disorder: a multi-center double-blind placebo-controlled study in outpatients. Am J Psychiatry. In press
7. Tollefson GD, Rampey AH Jr, Potvin JR, et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1994;51:559-567
8. Wheadon DE, Bushnell WD, Steiner M. A fixed dose comparison of 20, 40, or 60 mg paroxetine to placebo in the treatment of obsessive-compulsive disorder. Abstracts of Panels and Posters of the 32nd Annual Meeting of the American College of Neuropsychopharmacology; December 13-17, 1993; Honolulu, Hawaii
9. Chouinard G, Goodman W, Greist J, et al. Obsessive-compulsive disorder - treatment with sertraline: a multicenter study. Psychopharmacol Bull 1990;26:279-284
10. Jefferson JE, Greist JH. The pharmacotherapy of obsessive-compulsive disorder. Psychiatric Annals 1996;26(4):202-209
11. Palmer KJ, Benfield P. Fluvoxamine: an overview of its pharmacological properties and review of its therapeutic potential in non-depressive disorders. CNS Drugs 1994;1(1):57-87
12. Abramowicz M, ed. Fluvoxamine for obsessive-compulsive disorder. Med Lett Drugs Ther 1995;37(942):13-14
13. deVries MH, Raghoebar M, Mathlener IS, et al. Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects. Ther Drug Monit 1992;14:493-498
14. Wright S, Dawling S, Ashford JJ. Excretion of fluvoxamine in breast milk. Br J Clin Pharmacol 1991;31:209
15. Buist A, Norman TR, Dennerstein L. Breast-feeding and the use of psychotropic medication: a review. J Affect Disord 1990;19:197-206
16. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996;153(3):311-320
17. Fleishaker JC, Hulst LK. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol 1994;46:35-39
18. DeVane CL. Comparative safety and tolerability of selective serotonin reuptake inhibitors. Human Psychopharmacology 1995;10:S185-S193
19. DeQuardo JR, Roberts M. Elevated clozapine levels after fluvoxamine initiation. Am J Psychiatry 1996;153:840-841
20. Spina E, Campo GM, Avenoso A, et al. Interaction between fluvoxamine and imipramine/desipramine in four patients. Ther Drug Monit 1992;14: 194-196
21. Hartter S, Arand M, Oesch F, et al. Non-competitive inhibition of clomipramine N-demethylation of fluvoxamine. Psychopharmacology 1995;117: 149-153
22. Honig PK, Wortham DC, Zamani K, et al. Terfenadine-ketoconazole interaction. JAMA 1993;269:1513-1518
23. Von Moltke LL, Greenblatt DJ, Duan SX, et al. Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. J Clin Psychopharmacol 1966;16:104-112
24. Claritin (loratadine). Physicians' Desk Reference. Montvale, NJ: Medical Economics; 1997:2349-2350
25. Sale ME, Barbey JT, Woosley RL, et al. The electrocardiographic effects of cetirizine in normal subjects. Clin Pharmacol Ther 1994;56:295-301
26. Hoeschst Marion Roussel Data on file; Drug Topics Red Book Update, October 1996
27. Harmant J, van Rijckevorsel-Harmant K, de Barsy T, et al. Fluvoxamine: an antidepressant with low (or no) epileptogenic effect. Lancet 1990; 336:386
28. Trabert W, Hohagen F, Winkelman G, et al. A seizure, and electroencephalographic signs of a lowered seizure threshold, associated with fluvoxamine treatment of obsessive-compulsive disorder. Pharmacopsychiatry 1995;28(3):95-97
29. Hansten PD, Horn RJ, eds. Drug Interactions and Updates. Vancouver, Wash: Applied Therapeutics, Inc; 1996
30. Hendricks B, Floris M. A controlled pilot-study of the combination of fluvoxamine and lithium. Current Therapeutic Research, Clinical & Experimental 1991;4:106-110
31. Ohman R, Spigset O. Serotonin syndrome induced by fluvoxamine-lithium interaction. Pharmacopsychiatry 1993;16:263
32. Delgado PF, Price LH, Charney DS, et al. Efficacy of fluvoxamine in treatment-refractory depression. J Affect Disord 1988;15:55-60
33. Lejoyeux M, Ades J, Rouillon F. Serotonin syndrome: incidence, symptoms and treatment. CNS Drugs 1994;2:132-143
34. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148:705-713
35. Finley PR, Warner MD, Peabody CA. Clinical relevance of drug interactions with lithium. Clin Pharmacokinet 1995;29:172-191
36. Garnier R, Azoyan P, Chataigner D, et al. Acute fluvoxamine poisoning. J Int Med Res 1993;21:197-208
37. Adverse Reaction Information System Database. 1996. Solvay Duphar, Marietta, Ga.
38. Lapierre YD, Browne M, Horn E, et al. Treatment of major affective disorder with fluvoxamine. J Clin Psychiatry 1987;48:65-68
39. Conti L, Dell'Osso L, Re F, et al. Fluvoxamine maleate: double-blind clinical trial vs placebo in hospitalised depressed patients. Current Therapeutic Research 1988;43(3):468-480
40. Feighner JP, Boyer WF, Meredith CH, et al. A placebo-controlled inpatient comparison of fluvoxamine maleate and imipramine in major depression. Int Clin Psychopharmacol 1989;4:239-244
41. March JS, Kobak KA, Jefferson JW, et al. A double-blind, placebo-controlled trial of fluvoxamine versus imipramine in outpatients with major depression. J Clin Psychiatry 1990;51:200-202
42. Coleman BS, Block BA. Fluvoxamine maleate, a serotonergic antidepressant: in comparison with chlorimipramine. Prog Neuropsychopharmacol Biol Psychiatry 1982;6:475-478
43. de Wilde JE, Mertens C, Wakelin JS. Clinical trials of fluvoxamine vs chlorimipramine with single and three times daily dosing. Br J Clin Pharmacol 1982;15:427S-431S
44. Price LH, Goodman WK, Charney DS, et al. Treatment of severe obsessive-compulsive disorder with fluvoxamine. Am J Psychiatry 1987;144: 1059-1061
45. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
46. Perse TL, Greist JH, Jefferson JW, et al. Fluvoxamine treatment of obsessive-compulsive disorder. Am J Psychiatry 1988;144:1543-1548
47. Goodman WK, Price LH, Rasmussen SA, et al. The efficacy of fluvoxamine in obsessive compulsive disorder: a double-blind comparison with placebo. Arch Gen Psychiatry 1989;46:36-44
48. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale, I: development, use, and reliability. Arch Gen Psychiatry 1989;46:1006-1011
49. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale, II: validity. Arch Gen Psychiatry 1989;46:1012-1016
50. Goodman WK, Price LH, Delgado PL, et al. Specificity of serotonin reuptake inhibitors in the treatment of obsessive compulsive disorder: comparison of fluvoxamine and desipramine. Arch Gen Psychiatry 1990;47: 577-585
51. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-296
52. Mavissakalian M, Turner SM, Michelson L, et al. Tricyclic antidepressants in obsessive-compulsive disorder: antiobsessional or antidepressant agents? II. Am J Psychiatry 1985;142:572-576
53. Marks IM, Stern RS, Mawson D, et al. Clomipramine and exposure for obsessive-compulsive rituals. Br J Psychiatry 1980;136:1-25
54. Insel TR, Murphy DI, Cohen RM, et al. Obsessive-compulsive disorder: a double blind trial of clomipramine and clorgyline. Arch Gen Psychiatry 1983;40:605-612
55. Ackerman DL, Greenland S, Bystritsky A, et al. Predictors of treatment response in obsessive-compulsive disorder: multivariate analyses from a multicenter trial of clomipramine. J Clin Psychopharmacol 1994;14:247-254
56. Jenike MA, Baer L, Minichiello WE, et al. Concomitant obsessive-compulsive disorder and schizotypal personality disorder. Am J Psychiatry 1986; 143:530-533
57. McDougle CJ, Goodman WK, Leckman JF, et al. The efficacy of fluvoxamine in obsessive compulsive disorder: effects of comorbid chronic tic disorder. J Clin Psychopharmacol 1993;13(5):354-358
58. Pigott TA, Pato MT, Bernstein SE, et al. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder: behavioral and biological results. Arch Gen Psychiatry 1990;47:926-932
59. Jenike MA, Baer L, Greist JH. Clomipramine versus fluoxetine in obsessive-compulsive disorder: a retrospective comparison of side effects and efficacy. J Clin Psychopharmacol 1990;10:122-124
60. Griest JH, Jefferson JW, Kozak KA, et al. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder: a meta-analysis. Arch Gen Psychiatry 1995;52:53-60
61. Wachter KW. Disturbed by meta-analysis? Science 1988;241:1407-1408
62. Koran LM, McElroy SL, Davidson JRT, et al. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison. J Clin Psychopharmacol 1996;16:121-129
63. Smeraldi E, Erzegovesi S, Blanchi I, et al. Fluvoxamine vs clomipramine treatment in obsessive-compulsive disorder: a preliminary study. New Trends in Experimental and Clinical Psychiatry 1992;7(2):63-65
64. Tamimi RR, Mavissakalian MR, Jones B, et al. Clomipramine versus fluvoxamine in obsessive-compulsive disorder. Ann Clin Psychiatry 1991;3: 275-279
65. Freeman CPL, Trimble MR, Deakin JFW, et al. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. J Clin Psychiatry 1994;55:301-305
66. Mavissakalian MR, Jones B, Olson S. Absence of placebo response in obsessive-compulsive disorder. J Nerv Ment Dis 1990;178:268-270
67. Steiner M, Bushnell W, Gergel I, et al. Long-term treatment and prevention of relapse of OCD with paroxetine. In: New Research Program and Abstracts of the 148th Annual Meeting of the American Psychiatric Association; May 20-25, 1995; Miami, Fla. Abstract NR354:150
68. Ravizza L, Barzega G, Bellino S, et al. Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors. Psychopharmacol Bull 1996;32(1):167-173
69. Mallya GK, White K, Waternaux C, et al. Short-and long-term treatment of obsessive-compulsive disorder with fluvoxamine. Ann Clin Psychiatry 1992;4(2):77-80
70. Pato MT, Zohar-Kadouch R, Zohar J, et al. Return of symptoms after discontinuation of clomipramine in patients with obsessive compulsive disorder. Am J Psychiatry 1988;145:1521-1525
71. Leonard HL, Swedo SE, Lenane MC, et al. A double-blind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessive-compulsive disorder. Arch Gen Psychiatry 1991; 48:922-927
72. Pato MT, Hill JL, Murphy DL. A clomipramine dosage reduction in the course of long-term treatment of obsessive-compulsive disorder patients. Psychopharmacol Bull 1990;26:211-214
73. Back B, Uhde TW. Treatment of elective mutism with fluoxetine: a double-blind, placebo controlled study. J Am Acad Child Adolesc Psychiatry 1994; 33(7):1000-1006
74. Simeon JG, Dinicola VF, Ferguson HB, et al. Adolescent depression: a placebo controlled fluoxetine treatment study and follow-up. Prog Neuropsychopharmacol Biol Psychiatry 1990;14:791-795
75. Geller DA, Biederman J, Reed ED, et al. Similarities in response to fluoxetine in the treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 1995;34(1):36-44
76. Cook EH Jr, Rowlett R, Jaselskis C, et al. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry 1992;31:739-745
77. Apter A, Ratzoni G, King RA, et al. Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression. J Am Acad Child Adolesc Psychiatry 1994;33(3):342-348
78. Riddle MA, Claghom J, Gaffney G, et al. A controlled trial of fluvoxamine for OCD in children and adolescents. Biol Psychiatry 1996:39(7):568
79. Diaferia G, Mundo E, Blanchi Y, et al. Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description. J Clin Psychopharmacol 1994;14:78-79
80. Fennig S, Naisberg Fennig S, Pato M, et al. Emergence of Symptoms of Tourette's syndrome during fluvoxamine treatment of obsessive-compulsive disorder. British J Psychiatry 1994;164:839-841
81. Goodman WK, McDougle CJ, Byerly MJ, et al. New approaches to treatment-refractory obsessive compulsive disorder. In: Montgomery S, Halbreich U, eds. Pharmacotherapy of Mood and Cognition. In press
82. Greist JH. An integrated approach to treatment of obsessive compulsive disorder. J Clin Psychiatry 1992;53(4. suppl):38-41
83. Mattes JA. Fluvoxamine in obsessive-compulsive nonresponders to clomipramine or fluoxetine [letter]. Am J Psychiatry 1994;151:1524
84. Greist J, Chouinard G, DuBoff E, et al. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 1995;52:289-295
85. Byerly WJ, Goodman WK, Christensen R. High doses of sertraline for treatment-resistant obsessive-compulsive disorder [letter]. Am J Psychiatry 1996;153:1232-1233
86. Rasmussen SA. Lithium and tryptophan augmentation in clomipramine resistant obsessive-compulsive disorder. Am J Psychiatry 1984;141: 1283-1285
87. Mattes JA. A pilot study of combined trazodone and tryptophan in obsessive-compulsive disorder. Int Clin Psychopharmacol 1986;1:170-173
88. Hertzman PA, Blevins WL, Mayer J, et al. Association of the eosinophiliamyalgia syndrome with the ingestion of tryptophan. N Eng J Med 1990; 322:869-873
89. Hollander E, DeCaria CM, Schneier FR, et al. Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment. J Clin Psychiatry 1990;51:119-123
90. Judd FK, Chua P, Norman LC, et al. Fenfluramine augmentation of clomipramine treatment of obsessive compulsive disorder. Aust NZJ Psychiatry 1991;25:412-414
91. Pigott TA, Pato MT, L'Heureux F, et al. A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1991;11: 242-248
92. McDougle CJ, Price LH, Goodman WK, et al. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. J Clin Psychopharmacol 1991;11:175-184
93. McDougle CJ, Goodman WK, Leckman JF, et al. Limited therapeutic effect of the addition of buspirone in fluvoxamine-refractory obsessive compulsive disorder. Am J Psychiatry 1993;150:647-649
94. Pigott TA, L'Heureux F, Hill JH, et al. A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated OCD patients. J Clin Psychopharmacol 1992;12:11-18
95. Grady TA, Pigott TA, L'Heureux F, et al. Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. Am J Psychiatry 1993;150:819-821
96. Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 1994;51:248-251
97. Hoyer D. Functional correlates of serotonin 5-HT1 recognition sites. Journal of Receptor Research 1988;8:59-81
98. Tricklebank M, Forler C, Fozard J. The involvement of subtypes of the 5-HT1 receptor and of catecholaminergic systems in the behavioral response to 8-hydroxy-2-(di-n-propylamino) tetralin in the rat. Eur J Pharmacol 1984;106:271-282
99. Coccaro E, Gabriel S, Siever L. Buspirone challenge: preliminary evidence for a role for central 5-HT1A receptor function in impulsive aggressive behavior in humans. Psychopharmacol Bull 1990;26:393-405
100. Anderson IM, Cowen PJ. Effect of pindolol on endocrine and temperature responses to buspirone in healthy volunteers. Psychopharmacology 1992;106:428-432
101. Blier P, Bergeron R. Sequential administration of augmentation strategies in treatment-resistant obsessive-compulsive disorder: preliminary findings. Int Clin Psychopharmacol 1966;11:37-44
102. Simeon JG, Thatte S, Wiggins D. Treatment of adolescent obsessive-compulsive disorder with a clomipramine-fluoxetine combination. Psychopharmacol Bull 1990;26:285-290
103. Thoren P, Asberg M, Cronholm B, et al. Clomipramine treatment of obsessive-compulsive disorder, I: a controlled clinical trial. Arch Gen Psychiatry 1980;37:1281-1285
104. Szegedi A, Wetzel H, Leal M, et al. Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data. J Clin Psychiatry 1996;57:257-264
105. Rosenstein DL, Takeshita J, Nelson JC. Fluoxetine-induced elevation and prolongation of tricyclic levels in overdose [letter]. Am J Psychiatry 1991;148:807
106. Goodman WK, McDougle CJ, Price LH, et al. Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive compulsive disorder? J Clin Psychiatry 1990;51(8, suppl):36-43
107. McDougle CJ, Goodman WK, Leckman JF, et al. Haloperidol addition in fluvoxamine-refractory obsessive compulsive disorder: a double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 1994;51:302-308
108. Leckman JF, Pauls DL, Cohen DJ. Tic disorders. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:1665-1674
109. Holzer JC, Goodman WK, McDougle CJ, et al. Obsessive-compulsive disorder with and without a chronic tic disorder: a comparison of symptoms in 70 patients. Br J Psychiatry 1994;164:469-473
110. Pauls DL, Towbin KE, Leckman JF, et al. Gilles de la Tourette's syndrome and obsessive-compulsive disorder: evidence supporting a genetic relationship. Arch Gen Psychiatry 1986;43:1180-1182
111. Pauls DL, Alsobrook JP, Goodman WK, et al. A family study of obsessive compulsive disorder. Am J Psychiatry 1995;152:76-84
112. Riddle MA, Leckman JF, Hardin MT, et al. Fluoxetine treatment of obsessions and compulsions in patients with Tourette's syndrome. Am J Psychiatry 1988;145:1173-1174
113. Delgado PL, Goodman WK, Price LH, et al. Fluvoxamine/pimozide treatment of concurrent Tourette's and obsessive-compulsive disorder. Br J Psychiatry 1990;157:762-765
114. McDougle CJ, Goodman WK, Price LH, et al. Neuroleptic addition in fluvoxamine-refractory obsessive compulsive disorder: an open case series. Am J Psychiatry 1990;147:652-654
115. Hawkridge S, Stein DJ, Bouwer C. Combined pharmacotherapy for TS and OCD. J Am Acad Child Adolesc Psychiatry 1996;35(6):703
116. George MS, Trimble MR, Robertson MM. Fluvoxamine and sulpiride in comorbid obsessive-compulsive disorder and Gilles de la Tourette syndrome. Human Psychopharmacology 1993;8:327-334
117. Lombroso PJ, Scahill L, King RA, et al. Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report. J Am Acad Child Adoles Psychiatry 1995;34(9):1147-1152
118. McDougle CJ, Fleischmann RL, Epperson CN, et al. Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. J Clin Psychiatry 1995;56:526-528
119. McElroy SL, Hudson JI, Phillips KA, et al. Clinical and theoretical implications of a possible link between obsessive-compulsive and impulse control disorders. Depression 1993;1:121-132
120. Rasmussen SA, Commentary: obsessive compulsive spectrum disorders. J Clin Psychiatry 1994;55:89-91
121. Hollander E, Cohen LJ. Psychobiology and Psychopharmacology of compulsive spectrum disorders. In: Oldham JM, Hollander E, Skodol AE, eds. Impulsivity and Compulsivity. Washington, DC: American Psychiatric Press; 1996
122. Swedo SE, Leonard HL, Rapoport JL, et al. A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). N Engl J Med 1989;321:497-501
123. Leonard HL, Lenane MC, Swedo SE, et al. A double-blind comparison of clomipramine and desipramine treatment of severe onychophagia (nail biting). Arch Gen Psychiatry 1991;48:821-827
124. Gordon CT, State RC, Nelson JE, et al. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry 1993;50:441-447
125. Kruesi MJ, Fine S, Valladares L, et al. Paraphilias: a double-blind cross-over comparison of clomipramine versus desipramine. Arch Sex Behav 1992;21(6):587-593
126. Swedo SE, Rapoport JL, Leonard HL, et al. Regional cerebral glucose metabolism of women with trichotillomania. Arch Gen Psychiatry 1991; 48:828-833
127. Phillips KA. Body dysmorphic disorders: the distress of imagined ugliness. Am J Psychiatry 1991;148:1138-1149
128. Barsky AJ. Hypochondriasis and obsessive compulsive disorder. Psychiatr Clin North Am 1992;15(4):791-801
129. Fallon BA, Klein BW, Liebowitz MR. Hypochondriasis: treatment strategies. Psychiatric Annals 1993;23(7):374-381
130. Kaye WH, Weltzin TE, Hsu LKG, et al. Patients with anorexia nervosa have elevated scores on the Yale-Brown Obsessive-Compulsive Scale. Int J Eat Disord 1992;12(1):57-62
131. Hudson JI, Carter WP, Pope HG Jr. Antidepressant treatment of binge-eating disorder: research findings and clinical guidelines. J Clin Psychiatry 1996;57(suppl 8):73-79
132. Warnock JK, Kestenbaum T. Pharmacologic treatment of severe skin-picking behaviors in Prader-Willi syndrome: two case reports. Arch Dermatol 1992;128(12):1623-1625
133. Hellings JA, Warnock JK. Self-injurious behavior and serotonin in Prader-Willi syndrome. Psychopharmacology Bull 1994;30(2):245-250
134. Christenson GA, Mackenzie TB, Mitchell JE. Characteristics of 60 adult chronic hair pullers. Am J Psychiatry 1991;148:365-370
135. Swedo SE, Leonard HI. Trichotillomania: an obsessive-compulsive spectrum disorder? Psychiatr Clin North Am 1992;15:777-790
136. DeCaria CM, Hollander E, Grossman R, et al. Diagnosis, neurobiology, and treatment of pathological gambling. J Clin Psychiatry 1996;57(suppl 8):80-84
137. McElroy SL, Keck PE Jr, Phillips KA. Kleptomania, compulsive buying, and binge-eating disorder. J Clin Psychiatry 1995;56(suppl 4):14-26
138. Black DW. Compulsive buying: a review. J Clin Psychiatry 1996;57 (suppl 8):50-55
139. Simeon D, Hollander E, Stein DJ, et al. Body dysmorphic disorder in the DSM-IV field trial for obsessive-compulsive disorder. Am J Psychiatry 1995;152:1207-1209
140. Phillips KA, McElroy SL. An open-label study of fluvoxamine in body dysmorphic disorder. Biol Psychiatry 1996;39(7):625
141. Hollander E, Cohen L, Simeon D, et al. Fluvoxamine treatment of body dysmorphic disorder. J Clin Psychopharmacol 1994;14:75-77
142. Hollander E, Cohen LJ, Simeon D. Body dysmorphic disorder. Psychiatric Annals 1993;23(7):359-364
143. Fallon BA, Liebowitz MR, Salman E, et al. Fluoxetine for hypochondriacal patients without major depression. J Clin Psychopharmacol 1993;13: 438-441
144. Thiel A, Broocks A, Ohlmeier M, et al. Obsessive-compulsive disorder among patients with anorexia nervosa and bulimia nervosa. Am J Psychiatry 1995;152:72-75
145. Pigott TA, Altemus M, Rubenstein CS, et al. Symptoms of eating disorders in patients with obsessive-compulsive disorder. Am J Psychiatry 1991;148:1552-1557
146. Kaye WH, Weltzin T, Hsu LKG. Relationship between anorexia nervosa and obsessive and compulsive behaviors. Psychiatric Annals 1993;23 (7):365-372
147. Jarry JL, Vaccarino FJ. Eating disorder and obsessive-compulsive disorder: neurochemical and phenomenological commonalities. J Psychiatry Neurosci 1996;21(1):36-48
148. Ayuso-Gutierrez JL, Palazon M, Ayuso-Mateos JL. Open trial of fluvoxamine in the treatment of bulimia nervosa. Int J Eat Disord 1994;15: 245-249
149. Spigset O, Pleym H. A case report of successful treatment of bulimia nervosa with fluvoxamine. Pharmacopsychiatry 1991;24:180
150. Gardiner HM, Freeman CPL, Jesinger DK, et al. Fluvoxamine: an open pilot study in moderately obese female patients suffering from atypical eating disorders and episodes of bingeing. International Journal of Obesity and Related Metabolic Disorder 1993;17:301-305
151. Hudson JI, McElroy SL, Raymond NC, et al. Fluvoxamine treatment of binge eating disorder: a multicenter, placebo-controlled trial. In: New Research Program and Abstracts of the 1994 American Psychiatric Association Annual Meeting; May 26, 1994; Philadelphia, Pa. Abstract NR620:218
152. Fluoxetine Bulimia Nervosa Collaborative Study Group. Fluoxetine in the treatment of bulimia nervosa: a multi-center, placebo-controlled, double-blind trial. Arch Gen Psychiatry 1992;49:139-147
153. Fichter MM, Kruger R, Rief W, et al. Fluvoxamine in prevention of relapse in bulimia nervosa: effects on eating-specific psychopathology. J Clin Psychopharmacology 1995;16:9-18
154. Abell CA, Farquhar DL, Galloway SM, et al. Placebo controlled doubleblind trial of fluvoxamine maleate in the obese. J Psychosom Res 1986; 30:143-146
155. Flament MF, Corcos M, Igoin L, et al. Treatment of normal-weight bulimia nervosa with fluvoxamine: negative results from a double blind study with 103 outpatients. Presented at the WPA-regional symposium, "Developmental Issues in Psychiatry"; July 1994:10-14; Lisbon, Portugal
156. McDougle CJ, Kresch BA, Goodman WK, et al. A case controlled study of repetitive thoughts and behaviors in adults with autistic disorder and obsessive compulsive disorder. Am J Psychiatry 1995;152:772-777
157. McDougle CJ, Price LH, Goodman WK. Fluvoxamine treatment of coincident autistic disorder and obsessive-compulsive disorder: a case report. J Autism Dev Disord 1990;20(4):537-543
158. Harvey RJ, Cooray SE. The effective treatment of severe repetitive behaviour with fluvoxamine in a 20 year old autistic female. Int Clin Psychopharmacol 1995;10:201-203
159. Christenson GA, Crow SJ. The characterization and treatment of trichotillomania. J Clin Psychiatry 1996;57(suppl 8):42-49
160. Christenson GA, Mackenzie TB, Mitchell JE, et al. A placebo-controlled double-blind crossover study of fluoxetine in trichotillomania. Am J Psychiatry 1991;148:1566-1571
161. Streichenwein SM, Thomby JI. A long-term, placebo-controlled cross-over trial of the efficacy of fluoxetine for trichotillomania. Am J Psychiatry 1995;152:1192-1196
162. Hollander E, Frenkel M, DeCaria C, et al. Treatment of pathological gambling with clomipramine [letter]. Am J Psychiatry 1992;149:710-711
163. Wong CM, Hollander E. New dimensions in the OCD spectrum: autism, pathologic gambling, and compulsive buying. Primary Psychiatry 1996: 20-26, 29-34
164. McElroy SL, Keck PE Jr, Pope HG Jr, et al. Compulsive buying: a report of 20 cases. J Clin Psychiatry 1994;55:242-248
165. Black DW. The case of the women who couldn't stop shopping. Menninger Letter 1995;3:3
166. Travin S. Compulsive sexual behaviors. Psychiatr Clin North Am 1995; 18(1):155-169
167. Stein DL, Hollander E, Anthony DT, et al. Serotonergic medications for sexual obsessions, sexual addictions, and paraphilias. J Clin Psychiatry 1992;53:267-271
168. Zohar J, Kaplan Z, Benjamin J. Compulsive exhibitionism successfully treated with fluvoxamine: a controlled case study. J Clin Psychiatry 1994;55:86-88
169. Dominguez RA, Goodnick PJ. Adverse events after the abrupt discontinuation of paroxetine. Pharmacotherapy 1995;15(6):778-780
170. Frost L. Shock-like sensations after discontinuation of selective serotonin reuptake inhibitors [letter]. Am J Psychiatry 1995;152:810
171. Barr LC, Price LH, Goodman WK. Physical symptoms associated with paroxetine discontinuation [letter]. Am J Psychiatry 1994;151:289
172. DeBattista C, Shatzbert AF. Physical symptoms associated with paroxetine withdrawal. Am J Psychiatry 1995;152:1235-1236
173. Bloch M, Stager SV, Braun AR, et al. Severe psychiatric symptoms associated with paroxetine withdrawal [letter]. Lancet 1995;346:57
174. Phillips SD. A possible paroxetine withdrawal syndrome [letter]. Am J Psychiatry 1995;152:645-646
175. Pyke RE. Paroxetine withdrawal syndrome [letter]. Am J Psychiatry 1995;152:149-150
176. Keuthen NJ, Cyr P, Ricciardi JA, et al. Medication withdrawal symptoms in obsessive-compulsive disorder patients treated with paroxetine. J Clin Psychopharmacol 1994;14:206-207
177. Mallya G, White K, Gunderson C. Is there a serotonergic withdrawal syndrome [letter]? Biol Psychiatry 1993;33:851-852
178. Black DW, Wesner R, Gabel J. The abrupt discontinuation of fluvoxamine in patients with panic disorder. J Clin Psychiatry 1993;54:146-149
179. Szabadi E. Fluvoxamine withdrawal syndrome. Br J Psychiatry 1992; 160:283-284
180. Louie AK, Lannon RA, Luriko JA. Withdrawal reaction after sertraline discontinuation. Am J Psychiatry 1994;151:450-451
181. Leiter FL, Nierenberg AA, Sanders KM, et al. Discontinuation reactions following sertraline. Biol Psychiatry 1995;38:694-695
182. Lauterbach EC. Fluoxetine withdrawal and thalamic pain. Neurology 1994;44:983-984
183. Stoukides JA, Stoukides CA. Extrapyramidal symptoms upon discontinuation of fluoxatine [letter]. Am J Psychiatry 1991;148:1263
184. Einbinder E. Fluoxetine withdrawal? [letter] Am J Psychiatry 1995;152: 1235
185. Bergeron R, Blier P. Cisapride for the treatment of nausea produced by selective serotonin reuptake inhibitors. Am J Psychiatry 1994;151:1084-1086
186. Wiseman LR, Faulds D. Cisapride: an updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs 1994;47:116-152
187. Aapro MS. 5-HT3 receptor antagonists: an overview of their present status and future potential in cancer therapy-induced emesis. Drugs 1991; 42:551-568
188. Propulsid (cisapride). Physicians' Desk Reference. Montvale, NJ: Medical Economics; 1997:1300-1301
189. Nierenberg AA, Adler LA, Peselow E, et al. Trazodone for antidepressant-associated insomnia. Am J Psychiatry 1994;151:1069-1072
190. Pigott TA, L'Heureux F, Rubenstein CS, et al. A double-blind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1992;12:156-162
191. Gitlin MJ. Psychotropic medications and their effects on sexual function: diagnosis, biology, and treatment approaches. J Clin Psychiatry 1994;55: 406-413
192. McCormick S, Olin J, Brotman AW. Reversal of fluoxetine-induced anorgasmia by cyproheptadine in two patients. J Clin Psychiatry 1990;51: 383-384
193. Zajecka J, Fawcett J, Schaff M, et al. The role of serotonin in sexual dysfunction: fluoxetine-associated orgasm dysfunction. J Clin Psychiatry 1991;52:66-68
194. Arnott S, Nutt D. Successful treatment of fluvoxamine-induced anorgasmia by cyproheptadine. Br J Psychiatry 1994;164:838-839
195. Feder R. Reversal of antidepressant activity of fluoxetine by cyproheptadine in three patients. J Clin Psychiatry 1991;52:163-164
196. Hollander E, McCarley A. Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers. J Clin Psychiatry I992;53:207-209
197. Jacobson FM. Fluoxetine-induced sexual dysfunction and an open trial of yohimbine. J Clin Psychiatry 1992;53:119-122
198. Balogh S, Hendricks SE, Kang J. Treatment of fluoxetine-induced anorgasmia with amantadine [letter]. J Clin Psychiatry 1992;53:212-213
199. Labbate LA, Pollack MH. Treatment of fluoxetine-nduced sexual dysfunction with bupropion: a case report. Ann Clin Psychiatry 1994;6(1):13-15
200. Rothschild AJ. Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday. Am J Psychiatry 1995;152: 1514-1516